TrialThe Lancet. Oncology2022

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.

Howard P Safran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.